894
Views
25
CrossRef citations to date
0
Altmetric
Review

Deprescribing in the Older Patient: A Narrative Review of Challenges and Solutions

, , ORCID Icon, & ORCID Icon
Pages 3793-3807 | Published online: 24 Jul 2021

References

  • Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70:989–995. doi:10.1093/gerona/glv013
  • Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86–88. doi:10.1038/clpt.2008.224
  • Hilmer SN, Wu H, Zhang M. Biology of frailty: implications for clinical pharmacology and drug therapy in frail older people. Mech Ageing Dev. 2019;181:22–28. doi:10.1016/j.mad.2019.111119
  • Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91:521–528. doi:10.1038/clpt.2011.258
  • Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989–995. doi:10.1016/j.jclinepi.2012.02.018
  • Wu H, Mach J, Le Couteur DG, Hilmer SN. Fall-related mortality trends in Australia and the United Kingdom: implications for research and practice. Maturitas. 2020;142:68–72. doi:10.1016/j.maturitas.2020.07.008
  • Wu H, Mach J, Le Couteur DG, Hilmer SN. Nationwide mortality trends of delirium in Australia and the United States from 2006 to 2016. Australas J Ageing. 2021. doi:10.1111/ajag.12926
  • Wu H, Le Couteur DG, Hilmer SN. Mortality trends of stroke and dementia: changing landscapes and new challenges. J Am Geriatr Soc. 2021. doi:10.1111/jgs.17322
  • Waller S. Reducing medication-related harm through quality use of medicines. J Pharm Pract Res. 2020;50:374–376. doi:10.1002/jppr.1692
  • Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication without harm. WHO’s third global patient safety challenge. Lancet. 2017;389:1680–1681. doi:10.1016/s0140-6736(17)31047-4
  • Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003;33:323–328. doi:10.1002/jppr2003334323
  • Reeve E, Gnjidic D, Long J, Hilmer S, Systematic A. Review of the EMERGING DEfiNITION of ‘Deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80:1254–1268. doi:10.1111/bcp.12732
  • Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–834. doi:10.1001/jamainternmed.2015.0324
  • Brodaty H, Aerts L, Harrison F, et al. Antipsychotic deprescription for older adults in long-term care: the halt study. J Am Med Dir Assoc. 2018;19(592–600.e7). doi:10.1016/j.jamda.2018.05.002
  • Wu H, Mach J, Gemikonakli G, et al. Polypharmacy results in functional impairment in mice: novel insights into age and sex interactions. J Gerontol a Biol Sci Med Sci. 2021. doi:10.1093/gerona/glab088
  • Huizer-Pajkos A, Kane AE, Howlett SE, et al. Adverse geriatric outcomes secondary to polypharmacy in a mouse model: the influence of aging. J Gerontol a Biol Sci Med Sci. 2016;71:571–577. doi:10.1093/gerona/glv046
  • Mach J, Gemikonakli G, Logan C, et al. Chronic Polypharmacy with Increasing Drug Burden Index (Dbi) exacerbates frailty and impairs physical function, with effects attenuated by deprescribing, in aged mice. J Gerontol a Biol Sci Med Sci. 2020. doi:10.1093/gerona/glaa060
  • Eroli F, Johnell K, Latorre Leal M, et al. Chronic polypharmacy impairs explorative behavior and reduces synaptic functions in young adult mice. Aging (Albany N Y). 2020;12:10147–10161. doi:10.18632/aging.103315
  • Hilmer SN. Calculating and using the drug burden index score in research and practice. Expert Rev Clin Pharmacol. 2018;11:1053–1055. doi:10.1080/17512433.2018.1528145
  • Liacos M, Page AT, Etherton-Beer C. Deprescribing in Older People. Aust Prescr. 2020;43:114–120. doi:10.18773/austprescr.2020.033
  • Reeve E, Moriarty F, Nahas R, et al. Review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf. 2018;17:39–49. doi:10.1080/14740338.2018.1397625
  • Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD, Feasibility T. Effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:583–623. doi:10.1111/bcp.12975
  • Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66:201–202. doi:10.4212/cjhp.v66i3.1261
  • Earl TR, Katapodis ND, Schneiderman SR, Shoemaker-Hunt SJ. Using deprescribing practices and the screening tool of older persons’ potentially inappropriate prescriptions criteria to reduce harm and preventable adverse drug events in older adults. J Patient Saf. 2020;16:S23–s35. doi:10.1097/pts.0000000000000747
  • Thompson W, Reeve E, Moriarty F, et al. Deprescribing: future directions for research. Res Soc Admin Pharm. 2019;15:801–805. doi:10.1016/j.sapharm.2018.08.013
  • Burghle A, Lundby C, Ryg J, et al. Attitudes Towards Deprescribing among Older Adults with Limited Life Expectancy and Their Relatives: a Systematic Review. Drugs Aging. 2020;37:503–520. doi:10.1007/s40266-020-00774-x
  • Caughey GE, Tait K, Vitry AI, Shakib S. Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. Patient Prefer Adherence. 2017;11:131–140. doi:10.2147/ppa.S118836
  • Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD, Benefits T. Harms of Deprescribing. Med J Aust. 2014;201:386–389. doi:10.5694/mja13.00200
  • Doherty AJ, Boland P, Reed J, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020;4:bjgpopen20X101096. doi:10.3399/bjgpopen20X101096
  • Reeve E, Jordan V, Thompson W, et al. Withdrawal of Antihypertensive Drugs in Older People. Cochrane Database Syst Rev. 2020. doi:10.1002/14651858.CD012572.pub2
  • Scott IA, Pillans PI, Barras M, Morris C. Using Emr-enabled computerized decision support systems to reduce prescribing of potentially inappropriate medications: a narrative review. Ther Advan Drug Saf. 2018;9:559–573. doi:10.1177/2042098618784809
  • Reeve E. Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practice. J Pharm Pract Res. 2020;50:98–107. doi:10.1002/jppr.1626
  • Australian Deprescribing Network (ADeN). Available from: https://australiandeprescribingnetwork.com.au/. Accessed May 5, 2021.
  • Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30:793–807. doi:10.1007/s40266-013-0106-8
  • Reeve E, Low LF, Hilmer SN. Beliefs and Attitudes Of Older Adults And Carers About Deprescribing Of Medications: A Qualitative Focus Group Study. Br J Gen Pract. 2016;66:e552–60. doi:10.3399/bjgp16X685669
  • Quality Use of Medicines to Optimise Ageing in Older Australians. Recommendations for a National Strategic Action Plan to Reduce Inappropriate Polypharmacy. NHMRC Cognitive Decline Partnership Centre, University of Sydney, in Collaboration with the Australian Deprescribing Network and NPS MedicineWise. Sydney, NSW, Australia. Available from: https://cdpc.sydney.edu.au/wp-content/uploads/2019/06/quality-use-of-medicines.pdf. Accessed March 1, 2021.
  • Steinman MA, Landefeld CS. Overcoming inertia to improve medication use and deprescribing. JAMA. 2018;320:1867–1869. doi:10.1001/jama.2018.16473
  • Medication without Harm. Global Patient Safety Challenge on Medication Safety. Geneva: World Health Organization; 2017. Available from:: https://www.who.int/patientsafety/medication-safety/medication-without-harm-brochure/en/. Accessed March 1, 2021.
  • Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS One. 2016;11:e0151066. doi:10.1371/journal.pone.0151066
  • Smith H, Miller K, Barnett N, et al. Person-centred care including deprescribing for older people. Pharmacy (Basel, Switzerland). 2019. doi:10.3390/pharmacy7030101
  • Jansen J, Naganathan V, Carter SM, et al. Too much medicine in older people? deprescribing through shared decision making. BMJ. 2016;353:i2893. doi:10.1136/bmj.i2893
  • Institute for Healthcare Improvement. What is an Age-Friendly Health System? Available from: http://www.ihi.org/Engage/Initiatives/Age-Friendly-Health-Systems/Pages/default.aspx. Accessed June 06, 2021.
  • Ulley J, Harrop D, Ali A, Alton S, Fowler Davis S. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatr. 2019;19:15. doi:10.1186/s12877-019-1031-4
  • McKean M, Pillans P, Scott IA. A medication review and deprescribing method for hospitalised older patients receiving multiple medications. Intern Med J. 2016;46:35–42. doi:10.1111/imj.12906
  • O’Mahony D. Stopp/Start Criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress. Expert Rev Clin Pharmacol. 2020;13:15–22. doi:10.1080/17512433.2020.1697676
  • Ng B, Duong M, Lo S, Le Couteur D, Hilmer S. Deprescribing perceptions and practice: reported by multidisciplinary hospital clinicians after, and by medical students before and after, viewing an E-Learning Module. Res Social Adm Pharm. 2021. doi:10.1016/j.sapharm.2021.03.002
  • Kashyap M, Thuermann P, Le Couteur DG, Abernethy DR, Hilmer SN. Iuphar international geriatric clinical pharmacology curriculum for medical students. Pharmacol Res. 2019;141:611–615. doi:10.1016/j.phrs.2019.01.032
  • Gillaizeau F, Chan E, Trinquart L, et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev. 2013;11:CD002894. doi:10.1002/14651858.CD002894.pub3
  • Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165. doi:10.1002/14651858.CD008165.pub4
  • Roshanov PS, Fernandes N, Wilczynski JM, et al. Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ. 2013;346:f657. doi:10.1136/bmj.f657
  • Monteiro L, Maricoto T, Solha I, Ribeiro-Vaz I, Martins C, Monteiro-Soares M. Reducing potentially inappropriate prescriptions for older patients using computerized decision support tools: systematic review. J Med Internet Res. 2019;21:e15385. doi:10.2196/15385
  • Bloomfield HE, Greer N, Linsky AM, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35:3323–3332. doi:10.1007/s11606-020-06089-2
  • Dalton K, O’Brien G, O’Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing. 2018;47:670–678. doi:10.1093/ageing/afy086
  • Iankowitz N, Dowden M, Palomino S, Uzokwe H, Worral P. The effectiveness of computer system tools on potentially inappropriate medications ordered at discharge for adults older than 65 years of age: a systematic review. JBI Libr Syst Rev. 2012;10:798–831. doi:10.11124/jbisrir-2012-68
  • Fujita K, Kushida K, Okada H, Moles RJ, Chen TF. Developing and testing a set of quality indicators for pharmacist home visit services: a mixed methods study in Japan. Br J Clin Pharmacol. 2021;87:1940–1952. doi:10.1111/bcp.14587
  • Lawrence M, Olesen F. Indicators of quality in health care. Eur J Gen Pract. 1997;3:103–108. doi:10.3109/13814789709160336
  • Fujita K, Moles RJ, Chen TF. Quality indicators for responsible use of medicines: a systematic review. BMJ Open. 2018;8:e020437–e020437. doi:10.1136/bmjopen-2017-020437
  • Hermann RC, Mattke S, Somekh D, et al. Quality Indicators for International Benchmarking of Mental Health Care. Int J Qual Health Care. 2006;18(Suppl 1):31–38. doi:10.1093/intqhc/mzl025
  • Fastbom J, Johnell K. National indicators for quality of drug therapy in older persons: the Swedish Experience from the first 10 years. Drugs Aging. 2015;32:189–199. doi:10.1007/s40266-015-0242-4
  • Scottish Government Model of Care Polypharmacy Working Group. Polypharmacy Guidance (2nd Edition) 2015. Available from: https://www.sehd.scot.nhs.uk/publications/dc20150415polypharmacy.pdf. Accessed March 31, 2021.
  • NSW Therapeutic Advisory Group. Inappropriate Polypharmacy Risk Assessment Tool (IPRAT) 2020. Available from: https://www.nswtag.org.au/wp-content/uploads/2020/11/Resource-Kit-for-Measuring-Strategies-to-Reduce-Harm-from-Polypharmacy_Nov2020.pdf. Accessed March 31, 2021.
  • Mendelson A, Kondo K, Damberg C, et al. The effects of pay-for-performance programs on health, health care use, and processes of care: a systematic review. Ann Intern Med. 2017;166:341–353. doi:10.7326/M16-1881
  • van den Berg MJ, Kringos DS, Marks LK, Klazinga NS. The Dutch health care performance report: seven years of health care performance assessment in the Netherlands. Health Res Policy Syst. 2014;12:1. doi:10.1186/1478-4505-12-1
  • Teichert M, Schoenmakers T, Kylstra N, et al. Quality Indicators for Pharmaceutical Care: a Comprehensive Set with National Scores for Dutch Community Pharmacies. Int J Clin Pharm. 2016;38:870–879. doi:10.1007/s11096-016-0301-x
  • Warholak TL, West D, Holdford DA. The educating pharmacy students and pharmacists to improve quality program: tool for pharmacy practice. J Am Pharm Assoc (2003). 2010;50:534–538. doi:10.1331/JAPhA.2010.10019
  • Heath I, Hippisley-Cox J, Smeeth L. Measuring performance and missing the point? BMJ. 2007;335:1075–1076. doi:10.1136/bmj.39377.387373.AD
  • Pencheon D. The Good Indicators Guide: Understanding How to Use and Choose Indicators. NHS institute for Innovation and Improvement; 2008. Available from: https://fingertips.phe.org.uk/documents/The%20Good%20Indicators%20Guide.pdf. Accessed March 31, 2021.
  • Shea BJ, Hamel C, Wells GA, et al. Amstar is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013–1020. doi:10.1016/j.jclinepi.2008.10.009
  • Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011;11:15. doi:10.1186/1471-2288-11-15
  • Viswanathan M, Patnode CD, Berkman ND, et al. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. J Clin Epidemiol. 2018;97:26–34. doi:10.1016/j.jclinepi.2017.12.004
  • Bühn S, Mathes T, Prengel P, et al. The risk of bias in systematic reviews tool showed fair reliability and good construct validity. J Clin Epidemiol. 2017;91:121–128. doi:10.1016/j.jclinepi.2017.06.019
  • Pieper D, Buechter R, Jerinic P, Eikermann M. Overviews of reviews often have limited rigor: a systematic review. J Clin Epidemiol. 2012;65:1267–1273. doi:10.1016/j.jclinepi.2012.06.015
  • Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67:368–375. doi:10.1016/j.jclinepi.2013.11.007
  • Cardona M, Stehlik P, Fawzy P, et al. Effectiveness and sustainability of deprescribing for hospitalized older patients near end of life: a systematic review. Expert Opin Drug Saf. 2021;20:81–91. doi:10.1080/14740338.2021.1853704
  • Kua CH, Mak VSL, Huey lee SW. Health outcomes of deprescribing interventions among older residents in nursing homes: a systematic review and meta-analysis. J Am Med Dir Assoc. 2019;20:362–372.e11. doi:10.1016/j.jamda.2018.10.026
  • Shrestha S, Poudel A, Steadman K, Nissen L. Outcomes of deprescribing interventions in older patients with life-limiting illness and limited life expectancy: a systematic review. Br J Clin Pharmacol. 2020;86:1931–1945. doi:10.1111/bcp.14113
  • Nakham A, Myint PK, Bond CM, Newlands R, Loke YK, Cruickshank M. Interventions to reduce anticholinergic burden in adults aged 65 and older: a systematic review. J Am Med Dir Assoc. 2020;21:172–180.e5. doi:10.1016/j.jamda.2019.06.001
  • Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35:303–319. doi:10.1007/s40266-018-0536-4
  • Wilsdon TD, Hendrix I, Thynne TR, Mangoni AA. Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults. Drugs Aging. 2017;34:265–287. doi:10.1007/s40266-017-0442-1
  • Reeve E, Ong M, Wu A, et al. Review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol. 2017;73:927–935. doi:10.1007/s00228-017-2257-8
  • Johansson T, Abuzahra ME, Keller S, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:532–548. doi:10.1111/bcp.12959
  • Curtin D, Jennings E, Daunt R, et al. Deprescribing in older people approaching end of life: a randomized controlled trial using stoppfrail criteria. J Am Geriatr Soc. 2020;68:762–769. doi:10.1111/jgs.16278
  • New South Wales Therapeutic Advisory Group (NSW TAG) Polypharmacy Quality Use of Medicines (QUM) Indicators. Available from: https://www.nswtag.org.au/qum-indicators/. Accessed May 6, 2021.